Next-Generation IL6/IL6R Nanobody Solution for Advanced Liver Disease Therapy

VHH-P739 is a novel humanized nanobody engineered to specifically target interleukin 6 (IL6) and the interleukin 6 receptor (IL6R). Developed from a camelid-derived single domain format and expressed in ExpiHEK cells, VHH-P739 is currently undergoing biological testing and demonstrates strong potential as a new therapeutic modality for patients with liver diseases. By focusing on IL6 and IL6R, both well-established mediators in liver pathology, VHH-P739 aims to address critical aspects of disease progression, inflammation, and fibrosis within hepatic conditions. This nanobody platform offers a promising addition to targeting inflammatory pathways implicated in liver pathologies.

Licensing Opportunity

VHH-P739 is available for out-licensing and collaborative development partnerships. We welcome inquiries from biopharmaceutical companies interested in advancing next-generation liver disease therapeutics with a novel nanobody platform.

Development Phase

Modality

VHH-P739 represents a cutting-edge single domain antibody, often termed nanobody, derived from camelid heavy chain antibody variable domains. Its compact, monomeric structure allows for high solubility and exceptional tissue penetrance—key features for effectively reaching targets within dense liver tissue. As it is expressed in ExpiHEK cells, VHH-P739 is optimally configured for recombinant scalability and consistent bioactivity. The small size and robust stability of nanobodies support their favorable pharmacokinetics and manufacturability, offering pronounced advantages in targeting hepatic lesions and minimizing off-target toxicities. These structural properties position VHH-P739 as a particularly attractive modality for treating liver diseases, where comprehensive tissue access and stability are essential.

Target

IL6 and IL6R are pivotal molecular targets implicated in inflammation and immune regulation. IL6 is a multifunctional cytokine, whereas IL6R acts as its primary cell surface receptor, predominantly expressed on hepatocytes, immune cells, and select endothelial populations. Dysregulation of the IL6/IL6R pathway is tightly linked to hepatic inflammation, fibrogenesis, and the progression of multiple liver diseases. Targeting IL6 and IL6R interrupts disease-associated signaling cascades, providing scientific rationale for their selection in therapeutic development. The strategic focus on both IL6 and IL6R with VHH-P739 allows for comprehensive modulation of this axis, addressing pathologic signaling in liver diseases and offering distinct differentiation and potential clinical value.

Mechanism of Action

VHH-P739 exerts its therapeutic effect by directly binding to IL6 and IL6R, thereby modulating their interaction and signal transduction. As an anti-IL6 and anti-IL6R agent, VHH-P739 is designed to intercept the formation of the pro-inflammatory IL6/IL6R complex and prevent downstream signaling events that fuel chronic hepatic inflammation and fibrotic remodeling. This antagonistic mechanism holds promise for dampening aberrant cytokine activity and restoring immune balance in liver pathologies. Additionally, the nanobody platform provides a versatile basis for further engineering—enabling development into bispecific antibodies, antibody-drug conjugates, or fusion proteins for expanded therapeutic reach within inflammatory and fibrotic liver diseases.

Liver Diseases

Liver diseases encompass a diverse array of acute and chronic conditions, including viral hepatitis, alcoholic and non-alcoholic fatty liver disease, cirrhosis, and hepatocellular carcinoma. Globally, liver diseases are among the leading causes of morbidity and mortality, contributing substantially to health system burdens. Current therapeutic approaches range from antiviral medications and lifestyle modifications to systemic immunomodulators and, in advanced cases, liver transplantation. However, these interventions frequently encounter limitations, such as incomplete disease control, progression to irreversible liver damage, and limited organ availability for transplantation. The IL6/IL6R axis plays a central role in liver inflammation and fibrosis, marking it as a highly validated, but inadequately addressed, target in current therapeutics. By specifically disrupting this pathway, VHH-P739 offers the potential to modify disease progression at its root and address key unmet medical needs in liver disease management.